Results 231 to 240 of about 15,269 (294)
Cytotoxic lymphocytes counteract viral type I interferon immune evasion. [PDF]
Schakelaar MY +10 more
europepmc +1 more source
Poorly differentiated lung adenocarcinomas with concurrent anaplastic lymphoma kinase (ALK) and CD30 expression closely mimic ALK‐positive anaplastic large‐cell lymphoma, creating a significant diagnostic pitfall. Accurate classification requires comprehensive integration of clinical, radiologic, morphologic, immunophenotypic and molecular findings ...
Jietian Jin +6 more
wiley +1 more source
Cytotoxic CD4+ T cells in cancer: an emerging target for next-generation anticancer immunotherapy? [PDF]
van Wandeloo IMB +4 more
europepmc +1 more source
A PD1‐CD137L fusion protein converts the immunoinhibitory PD‐L1 to an immunostimulatory signal and is more effective than targeting PD‐L1 and CD137 separately. ABSTRACT Tumour immune evasion frequently involves PD‐L1‐mediated inhibition of T cell activity, limiting the efficacy of PD1/PD‐L1 blockade, particularly in PD‐L1‐low or immunologically ‘cold ...
Runze Xia +10 more
wiley +1 more source
The effect of COVID-19 and sex differences on natural killer cell cytotoxicity. [PDF]
Dagar A +6 more
europepmc +1 more source
Abstract Anti‐B cell maturation antigen (BCMA) therapies, including antibody‐drug conjugates, chimeric antigen receptor T cells, and bispecific antibodies (bsAbs), have recently revolutionized the treatment landscape of multiple myeloma. This review outlines the biologic rationale for targeting BCMA and sheds light on the mechanism of action of bsAbs ...
Enrica Manzato +5 more
wiley +1 more source
Tuberculosis in Pregnancy: Challenges of Immune Protection. [PDF]
Yengkhom D, Weinberg A.
europepmc +1 more source
Targeted theranostic nanomedicine using targeted CT-imageable particles that release tebentafusp. [PDF]
Harada S, Sato T, Yoshioka K.
europepmc +1 more source
Forimtamig: a potent GPRC5D-targeted bispecific antibody in multiple myeloma. [PDF]
Ali H +4 more
europepmc +1 more source

